Australia's Bionomics Ltd. Files for IPO With U.S. SEC
23 11월 2021 - 8:34AM
Dow Jones News
By Stephen Nakrosis
Biopharmaceutical company Bionomics Ltd. filed for an initial
public offering with the U.S. Securities and Exchange Commission on
Monday.
The company's shares currently trade on the Australian
Securities Exchange under the symbol BNO. The company said it
planned to offer American depositary shares on the Nasdaq Global
Market under the symbol BNOX.
Bionomics said its lead product candidate, BNC210, is for acute
treatment of Social Anxiety Disorder and chronic treatment of
Post-Traumatic Stress Disorder. "There remains a significant unmet
medical need for the over 22 million patients in the United States
alone suffering from SAD and PTSD," the company said.
BVF Partners L.P. and Apeiron Investment Group Ltd. are listed
among the company's principal shareholders.
Bionomics didn't give an expected size for its offering, nor did
it provide an expected price range.
Evercore ISI, William Blair, Cantor, Berenberg and H.C.
Wainwright & Co. are listed as the offering's underwriters.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 22, 2021 18:19 ET (23:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bionomics (ASX:BNO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Bionomics (ASX:BNO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Bionomics Limited (호주 증권거래소)의 실시간 뉴스: 최근 기사 0
More Bionomics Limited News Articles